About Ticagrelor API
Therapeutic CategoryCardiovascular
CAS Number
274693-27-5
API Technology
Synthetic
Dose Form
Oral Solids
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, CEP Submitted, Brazil DMF, EUDMF, Canada DMF, Korea DMF, Russia DMF, China DMF
Mechanism of Action
Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Ticagrelor and its active metabolite are approximately equipotent.
Indication
BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the rate of stent thrombosis in patients who have been stented for treatment of ACS.
Related APIs
Amlodipine Besylate
Cardiovascular
Apixaban
Cardiovascular
Atorvastatin Calcium (Amorphous And Form 1)
Cardiovascular
Bempedoic Acid
Cardiovascular
Clopidogrel Bisulfate (Form 1)
Cardiovascular
Clopidogrel Bisulfate (Form 2)
Cardiovascular
Dabigatran Etexilate Mesylate
Cardiovascular
Doxazosin Mesylate
Cardiovascular
Ezetimibe
Cardiovascular
Fondaparinux Sodium
Cardiovascular
Lacidipine
Cardiovascular
Losartan Potassium
Cardiovascular
Mavacamten
Cardiovascular
Metoprolol Succinate
Cardiovascular
Ramipril
Cardiovascular
Rivaroxaban
Cardiovascular
Sacubitril / Valsartan
Cardiovascular
Tafamidis Free Acid
Cardiovascular
Tafamidis Meglumine
Cardiovascular
Ticagrelor
Cardiovascular
Treprostinil
Cardiovascular
Treprostinil Olamine
Cardiovascular
Valsartan
Cardiovascular
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!